GoodRx Holdings Inc. Achieves Modest Growth in Q4 Earnings
GoodRx Holdings Inc. (NASDAQ: GDRX) reported a revenue of $198.6 million for the fourth quarter, showing a slight year-over-year increase of 1%. However, this performance fell short compared to the management's expectations of around $200 million and the consensus estimate of approximately $199.75 million.
Yearly Sales Under Expectations
The total sales for the fiscal year reached $792.3 million, which did not meet the guidance aimed at around $794 million. The adjusted earnings per share (EPS) for the quarter was recorded at 9 cents, up from 8 cents in the same quarter last year, yet it missed the forecasted 10 cents.
Prescription Transactions Revenue Growth
During Q4, revenue from prescription transactions rose by 0.8% to $144.9 million. For the full year, prescription transaction revenue saw a more robust increase of 5%, totaling $577.5 million. This growth was fueled by a notable 7% organic increase in monthly active consumers, which included the positive performance of an integrated savings program.
Consumer Engagement Insights
As GoodRx closed out the fourth quarter, over 7 million consumers engaged with the platform for prescription-related services, with 6.6 million being monthly active users. Among them, approximately 684,000 were subscribed to various plans.
Subscription Revenue Decline
However, the subscription revenue saw a decline of 8% for the year, totaling $86.5 million. This drop was primarily attributed to a reduction in subscription plans following the discontinuation of the Kroger Savings Club partnership. In the fourth quarter alone, subscription revenue decreased by 10.7%, amounting to $20.68 million.
Pharma Manufacturer Solutions Surge
On a more positive note, revenue from pharma manufacturer solutions experienced a significant jump from $24.4 million to $28.1 million in Q4. For the full year, this segment surged by 26% to $107.2 million, mainly due to organic growth as GoodRx expands its market presence with drug manufacturers.
Adjusted EBITDA and Future Outlook
The company reported an adjusted EBITDA of $67.08 million for the fourth quarter and $260.2 million for the entire year. For fiscal year 2025, GoodRx anticipates a revenue outlook between $810 million and $840 million, reflecting a growth range of 2% to 6% compared to the consensus of $825.57 million. Adjusted EBITDA is expected to land between $270 million to $286 million.
Guidance for 2025
Looking ahead, GoodRx projects first-quarter 2025 revenues to fall between $201 million and $205 million, which indicates a growth rate of 2% to 4% against the consensus of $202.53 million. They also expect an adjusted EBITDA margin of about 33% for the quarter.
Stock Market Performance
In terms of stock performance, shares of GDRX have indicated an increase of 4.6%, reaching $5.12 at the latest market check.
Frequently Asked Questions
What were the Q4 revenue figures for GoodRx Holdings Inc.?
GoodRx reported a fourth-quarter revenue of $198.6 million, reflecting a 1% increase from the prior year.
How did GoodRx perform in terms of subscription revenue?
The company saw an 8% decrease in subscription revenue for 2024, totaling $86.5 million due to various factors including the end of a partnership program.
What was the adjustment in EPS for the quarter?
The adjusted EPS for GoodRx in Q4 was 9 cents, up from 8 cents the previous year but lower than the consensus estimate of 10 cents.
What is the future revenue forecast for GoodRx?
GoodRx anticipates a revenue outlook for fiscal 2025 between $810 million and $840 million.
What has driven the growth in pharma manufacturer solutions revenue?
The growth in pharma manufacturer solutions, which increased by 26% last year, is primarily attributed to organic market expansion and deeper engagement with pharmaceutical companies.
